Advanced pharma tech steroids

A transformation is not an end in itself. To sustain the momentum of change, especially in today’s volatile environment, companies need to plan for continuous improvement. In practical terms, that requires a culture of scrutinizing daily work and finding ways to do it better. Explaining what that means for his business, André Wyss, president of Novartis Business Services, said: “We continuously have to examine the technology, tools, and services we offer in order to find ways of making them even faster, more flexible, more consistent, and more cost efficient.”

The exact relations between science and technology in particular have been debated by scientists, historians, and policymakers in the late 20th century, in part because the debate can inform the funding of basic and applied science. In the immediate wake of World War II , for example, it was widely considered in the United States that technology was simply "applied science" and that to fund basic science was to reap technological results in due time. An articulation of this philosophy could be found explicitly in Vannevar Bush 's treatise on postwar science policy, Science – The Endless Frontier : "New products, new industries, and more jobs require continuous additions to knowledge of the laws of nature ... This essential new knowledge can be obtained only through basic scientific research." [18] In the late-1960s, however, this view came under direct attack, leading towards initiatives to fund science for specific tasks (initiatives resisted by the scientific community). The issue remains contentious, though most analysts resist the model that technology simply is a result of scientific research. [19] [20]

Key players in this domain include the MIT Clinical Machine Learning Group , whose precision medicine research is focused on the development of algorithms to better understand disease processes and design for effective treatment of diseases like Type 2 diabetes.  Microsoft’s Project Hanover  is using ML technologies in multiple initiatives, including a collaboration with the Knight Cancer Institute to develop AI technology for cancer precision treatment, with a current focus on developing an approach to personalize drug combinations for Acute Myeloid Leukemia (AML) .

Unless otherwise indicated or the context otherwise requires, references to the "Company", "we", "us" and "our" refer to Horizon Pharma plc and its consolidated subsidiaries, including its predecessor Horizon Pharma, Inc., or HPI. All references to "Vidara" are references to Horizon Pharma plc (formerly known as Vidara Therapeutics International Public Limited Company) and its consolidated subsidiaries prior to the effective time of the merger of the businesses of HPI and Vidara on September 19, 2014, or the Vidara Merger. The disclosures in this report relating to the pre-Vidara Merger business of Horizon Pharma plc, unless noted as being the business of Vidara prior to the Vidara Merger, pertain to the business of HPI prior to the Vidara Merger.  ... More ...  

Advanced pharma tech steroids

advanced pharma tech steroids

Unless otherwise indicated or the context otherwise requires, references to the "Company", "we", "us" and "our" refer to Horizon Pharma plc and its consolidated subsidiaries, including its predecessor Horizon Pharma, Inc., or HPI. All references to "Vidara" are references to Horizon Pharma plc (formerly known as Vidara Therapeutics International Public Limited Company) and its consolidated subsidiaries prior to the effective time of the merger of the businesses of HPI and Vidara on September 19, 2014, or the Vidara Merger. The disclosures in this report relating to the pre-Vidara Merger business of Horizon Pharma plc, unless noted as being the business of Vidara prior to the Vidara Merger, pertain to the business of HPI prior to the Vidara Merger.  ... More ...  

Media:

advanced pharma tech steroidsadvanced pharma tech steroidsadvanced pharma tech steroidsadvanced pharma tech steroidsadvanced pharma tech steroids